causaLens Partners With Mayo Clinic to Discover Biomarkers of Cancer Using Causal AI
causaLens , the London deep tech company delivering the future of AI, has utilized its Causal AI technology in an important step towards adopting non-invasive methods for screening and understanding cancer. New research demonstrates that Causal AI enables reliable early detection of cancers based on easy-to-administer and cost-effective blood tests.
Using a strictly data-driven approach, causaLens, which this year received investment from Dorilton Capital and Molten Ventures , discovered possible causal connections between the expression of genes and proteins and the manifestation and stage of colorectal cancer.
Colorectal cancer is the fourth most common cancer - with 147,950 cases annually - and one of the most lethal cancers - with 53,000 deaths per year.
At present, the only screening method used for colorectal cancer is colonoscopy, to identify and remove precursor lesions. However, this procedure is expensive and invasive, limiting reach for a type of cancer that is increasing by 2% a year among the under 50s, and requires ever-shorter screening intervals to prevent disease in higher-risk patients.
For these reasons, there is an urgent clinical need for techniques that can reliably detect early-stage colorectal cancers via non-invasive methods. The potential impact of causaLens’ research — undertaken in collaboration with academics from the Mayo Clinic, the prominent US medical research center — would be a significant improvement in the long-term prospects of patients with colorectal cancer.
causaLens is the pioneer of Causal AI — the only AI technology that is capable of discovering and reasoning with cause-and-effect relationships. Causal AI can root out spurious correlations in which two or more variables are associated but not causally related, due to either coincidence or the presence of a third, unseen factor.
The company has successfully delivered transformational outcomes across many sectors, from improving investment portfolio returns to mitigating supply chain disruptions and navigating public health crises.
Commenting on the company’s work in cancer research, Nicholas Chia, Assistant Professor of Biophysics, Mayo Clinic said:
“Causal AI is a fundamental scientific breakthrough and causaLens’ vision for Causal AI extends far beyond enterprise decision making. causaLens has the potential to disrupt a vast range of sectors and industries and has already demonstrated the value of its Causal AI technology in biological applications such as the discovery of cancer biomarkers"
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IL-ADAMS-STREET-PARTNERS5.10.2022 15:01:51 CEST | Press release
Brijesh Jeevarathnam to Succeed Kelly Meldrum as Global Head of Fund Investments at Adams Street Partners
MA-NETWITNESS5.10.2022 15:01:41 CEST | Press release
NetWitness Launches White Hat Wednesdays Conversation Series
CA-ANDERSEN-GLOBAL5.10.2022 14:35:35 CEST | Pressemeddelelse
Andersen Global udvider skatteekspertisen i Canada
CA-ESRI5.10.2022 14:02:00 CEST | Press release
Esri Partners with Digital Earth Africa to Support Sustainable Growth
SANDBOX-&-CO5.10.2022 14:01:50 CEST | Press release
Sandbox Brings on Board toucanBox, UK-Based Children’s Subscription Service, to Bolster Its Hands-on Learning Range
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom